A novel four-step system for screening angiogenesis inhibitors.
Angiogenesis exhibits a significant effect on tumor progression. Inhibiting angiogenesis may provide significant advantages over currently available therapeutics for cancer therapies thus, the development of a system of screening angiogenesis is essential. In the present study, a novel available system of screening angiogenesis inhibitors by four steps was developed. The chorioallantoic membrane (CAM), yolk sac membrane and early chick embryo blood island assay were initially performed to obtain possible antitumor compounds. The MMTV‑PyMT transgenic breast cancer mouse model was used for final screening and to confirm potential antitumor effects. Four angiogenesis inhibitors were isolated from 480 compounds, which were obtained from ICCB known bioactives library, by a combination of the CAM, yolk sac membrane and early chick embryo blood island assay. The MMTV‑PyMT mouse was treated with one of four agents and it was demonstrated that the tumor volume was significantly inhibited. These results demonstrate that the four‑step screening system is feasible.
Vascular Biology Research Institute, Guangdong Key Laboratory of Pharmaceutical Bioactive Substances, Guangdong Pharmaceutical University, Guangzhou, Guangdong 510006, P.R. China.
Qin
Q
Zhou
Cui-Ling
CL
Qi
Yan
Y
Li
Xiao-Dong
XD
He
Jiang-Chao
JC
Li
Qian-Qian
QQ
Zhang
Lan
L
Tian
Ming
M
Zhang
Zhe
Z
Han
Huiping
H
Wang
Xuesong
X
Yang
Li-Jing
LJ
Wang
D020533:Angiogenesis Inhibitors / Q000032:analysis* / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply / Q000187:drug effects / Q000473:pathology; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005260:Female; D057166:High-Throughput Screening Assays; D015674:Mammary Neoplasms, Animal / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D008324:Mammary Tumor Virus, Mouse / Q000502:physiology; D008566:Membranes / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000473:pathology; D015017:Yolk Sac / Q000098:blood supply / Q000187:drug effects
D020533:Angiogenesis Inhibitors; D004121:Dimethyl Sulfoxide
chorioallantoic  membrane; angiogenesis  inhibitor screening  system; yolk  sac  membrane; blood  island  model; MMTV‑PyMT mouse